Search results for: NICE
Filter search results
Valuing Health at the End of Life: A Review of Stated Preference Studies in the Social Sciences Literature
9 April 2018
…in England, where since 2009 NICE has adopted a supplementary policy in its technology appraisal programme that effectively applies a premium for life-extending end of life treatments. Public preferences have…
Progression-free Survival as a Surrogate Outcome for Overall Survival in Oncology
4 September 2018
When should progression-free survival be used as a surrogate for overall survival in oncology? A recent article in the International Journal of Technology Assessment in Health Care, co-authored by OHE…
End of Life Treatments, Societal Values, and ‘Overall’ Preference
12 February 2019
OHE’s Koonal Shah gave a presentation on societal values and the provision of end of life treatments at a Manchester Centre for Health Economics seminar. On 4th February, OHE’s Koonal…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
This research by a team of OHE and IHE researchers estimates the value added by second generation antipsychotics over their life-cycle in the UK and Sweden. It concludes that considering…
Realising the Broader Value of Vaccines in the UK
8 January 2020
Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided. However, compared to other…
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
Earlier this week, President Donald Trump signed an Executive Order to bring the prices Americans and U.S taxpayers pay for prescription drugs in line with those paid by similar nations….